Research graph
References from DUBHE-H-308 study protocol: rationale and adaptive design of a randomized, open-label, seamless phaseII/III trial of iparomlimab and tuvonralimab (QL1706)-based regimens versus sintilimab plus bevacizumab as first-line treatment for advanced hepatocellular carcinoma. Local targets link to admitted publications; unresolved targets remain external evidence.
10.3322/caac.21820
10.3322/caac.21820 · External reference
10.1111/liv.12818
10.1111/liv.12818 · External reference
10.1056/nejmra1713263
10.1056/nejmra1713263 · External reference
10.1056/nejmoa0708857
10.1056/nejmoa0708857 · External reference
10.1200/jco.2012.44.5643
10.1200/jco.2012.44.5643 · External reference
10.1016/s0140-6736(17)31046-2
10.1016/s0140-6736(17)31046-2 · External reference
10.1200/jco.22.00620
10.1200/jco.22.00620 · External reference
10.1056/nejmoa1915745
10.1056/nejmoa1915745 · External reference
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study
10.1016/s1470-2045(21)00252-7 · 2021 · External reference
10.1016/s0140-6736(23)00961-3
10.1016/s0140-6736(23)00961-3 · External reference
10.1016/j.annonc.2024.03.005
10.1016/j.annonc.2024.03.005 · External reference
10.1002/onco.13819
10.1002/onco.13819 · External reference
10.1158/1078-0432.ccr-23-2124
10.1158/1078-0432.ccr-23-2124 · External reference
10.1056/evidoa2100070
10.1056/evidoa2100070 · External reference
10.1200/jco.2024.42.17_suppl.lba4008
10.1200/jco.2024.42.17_suppl.lba4008 · External reference
Unresolved reference
External reference
10.1186/s13045-023-01445-1
10.1186/s13045-023-01445-1 · External reference
10.1038/s41392-023-01731-x
10.1038/s41392-023-01731-x · External reference
Efficacy and safety of iparomlimab and tuvonralimab in previously treated patients with recurrent or metastatic cervical cancer: a multicenter, open-label, single-arm, phase ii clinical trial (DUBHE-C-206)
10.1136/ijgc-2024-esgo.8 · 2024 · External reference
An open-label, multicenter, adaptive, phase Ib/II study of QL1706 or QL1604 plus bevacizumab as first-line treatment in patients with advanced hepatocellular carcinoma
10.1200/jco.2023.41.16_suppl.4077 · 2023 · External reference
10.1158/2159-8290.cd-20-1209
10.1158/2159-8290.cd-20-1209 · External reference
10.1016/j.crimmu.2022.05.003
10.1016/j.crimmu.2022.05.003 · External reference
10.1038/s41571-025-01055-5
10.1038/s41571-025-01055-5 · External reference
10.1038/onc.2009.356
10.1038/onc.2009.356 · External reference
10.1007/s13402-020-00552-2
10.1007/s13402-020-00552-2 · External reference
10.1016/j.jtho.2021.07.009
10.1016/j.jtho.2021.07.009 · External reference
10.3390/ijms252413590
10.3390/ijms252413590 · External reference
10.1080/10543406.2018.1535496
10.1080/10543406.2018.1535496 · External reference
10.1080/10543406.2015.1094807
10.1080/10543406.2015.1094807 · External reference
Iparomlimab and tuvonralimab (QL1706) with bevacizumab and/or chemotherapy in first-line (1L) treatment of advanced hepatocellular carcinoma (aHCC): a randomized, open-label, phase II/III study (DUBHE-H-308). ESMO 2024, abstrct #LBA 38
10.1016/j.annonc.2024.08.2278 · 2024 · External reference
Iparomlimab and tuvonralimab (QL1706) plus bevacizumab and/or chemotherapy in first-line treatment for advanced hepatocellular carcinoma: updated data from the phase ii part of DUBHE-H-308 study
10.1016/j.annonc.2025.08.2125 · 2025 · External reference
